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Abstract
Background: Cardiac magnetic resonance (CMR) is used in the diagnosis and risk stratifica-
tion of hypertrophic cardiomyopathy (HCM) and can detect myocardial replacement fibrosis (an 
independent predictor of adverse cardiac outcomes) using late gadolinium enhancement (LGE). 
Methods: We retrospectively analysed CMR studies carried out over a 2 year period identifying 
those which were diagnostic of HCM. 117 cases were analysed. Mean age of subjects was 53 years and  
78 (67%) were male. Mean ejection fraction (EF) was 68.3% with a mean left ventricular (LV) 
mass index of 89.4 g/m2. Hypertrophy was predominantly asymmetric in 94 (80%). 
Results: All subjects received gadolinium and 80 (68%) had evidence of LGE. LVEF was 
lower (67 vs. 71%; p = 0.015) and LV mass index higher (94 vs. 81 g/m2; p = 0.007) in the 
LGE group. The proportion of patients with at least 1 clinical risk factor for sudden cardiac 
death (SCD) was similar in groups with and without LGE (48% vs. 32%; p = 0.160). In this 
study, a significant proportion (62%) of patients without clinical risk factors for SCD were 
found to have LGE on CMR. These patients would not currently be considered for therapy with 
an implantable cardiac defibrillator. 
Conclusions: 1. Patients with HCM are at increased risk of SCD, but identifying patients 
who may benefit from implantable defibrillators is difficult. 2. LGE is associated with adverse 
cardiovascular outcomes in HCM, but is present in a large proportion of patients. 3. Many 
patients without clinical risk factors for SCD have LGE and would not currently be considered 
for an implantable cardiac device. (Cardiol J 2014; 21, 1: 29–32)
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Introduction
Cardiac magnetic resonance (CMR) is now 
widely used in the diagnosis and risk stratification 
of hypertrophic cardiomyopathy (HCM). It has 
several advantages over echocardiography inclu-
ding more accurate measurement of left ventricular 
function and mass, and it aids in the identification 
of apical HCM variants and alternative causes of 
hypertrophy such as athelets heart and Fabry’s 
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diseaes. Furthermore, it has the ability to demon-
strate areas of myocardial replacement fibrosis 
using late gadolinium enhancement (LGE) (Fig. 1) 
which is increasingly being recognised as an inde-
pendent predictor of adverse cardiac outcomes [1–6]. 
Several recently published reports have found an 
increased incidence of adverse cardiovascular events 
in patients with LGE compared to those without, and 
the sensitivity of clinical risk factors for prediction 
of sudden cardiac death (SCD) has been questioned. 
However previous studies have shown that LGE is 
present in a large proportion of patients with HCM, 
and therefore identifies too large a population to be 
useful as a single predictor. We sought to look at the 
occurence of LGE in our population and assess the 
association of LGE with clinical risk factors. 
Methods
We performed a retrospective analysis of all 
CMR studies carried out in a single center over 
a 24 month period from January 2010 to December 
2011. Data was collected on all patients in whom 
CMR findings were consistent with a diagnosis of 
HCM ie. a hypertrophied and non-dilated ventric-
le in the absence of another condition capable of 
producing the observed degree of hypertrophy [7]. 
A cut-off for maximal wall thickness of 15 mm 
was used in adults in keeping with current guide-
lines although some patients with maximal wall 
thickness less than 15 mm were included if there 
was a strong clinical suspicion of HCM based on 
a family history of the condition in at least one first 
degree relative. Patients who had left ventricular (LV) 
hypertrophy which was potentially due to another 
condition such as hypertension were excluded, as 
were patients who did not receive a gadolinium based 
contrast agent as part of the imaging protocol.
All studies were performed on a Siemens 
Avanto 1.5 T scanner. LGE images were obtained 
after administration of intravenous gadobenate 
demeglumine (0.2 mmol/kg). LV function and 
mass were analysed after manual identification of 
endocardial and epicardial borders. The amount of 
LGE was not measured quantitively but was noted 
to be present or absent. 
Patient demographics and occurence of clinical 
risk factors for SCD were obtained from review 
of clinical notes. CMR findings were taken from 
reports by level II or III accredited cardiologists. 
LV mass and function (indexed), distribution of 
hypertrophy and the presence of systolic anterior 
motion of the mitral valve (SAM) or elevated LV 
outflow tract (LVOT) velocities were noted.
As this was a retrospective analysis of patient 
records and no additional procedures beyond nor-
mal patient care were carried out, ethical approval 
and patient consent were not required.
Statistical analysis
Statistical analysis was carried out using SPSS 
v.17.0. Categorical variables were compared using 
c2 test. Continuous variables were compared using 
the independent students t-test. 
Results
One hundred and seventeen cases were inclu-
ded for analysis. Mean age of subjects was 53 ± 
± 15.8 years and 78 (67%) were male. Mean ejection 
fraction (EF) was 68.3 ± 8.5% with a mean LV mass 
index of 89.4 ± 26.7 g/m2. SAM was present in 
24 (21%) and 16 (14%) had an elevated LVOT velocity. 
The pattern of hypertrophy was predominantly 
asymmetric in 94 (80%), predominantly apical in 
13 (11%) and concentric in 10 (9%).
All subjects received gadolinium and some de-
gree of LGE was present in 80 (68%). There was no 
significant difference in prevalence of LGE based 
on gender (p = 0.115). LGE was more common in 
apical (79%) and concentric (80%) patterns of hy-
pertrophy compared to asymmetric (65%) although 
this difference was not statistically significant 
Figure 1. Late gadolinium enhancement within the in-
terventricular septum in a patient with hypertrophic 
cardiomyopathy.
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(p = 0.254). LVEF was lower (67 ± 8.5% vs. 71 ± 
± 8.0%; p = 0.015) and LV mass index higher (94 ± 
± 27.9 g/m2 vs. 81 ± 21.7 g/m2; p = 0.007) in the 
LGE group.
Fifty (43%) of the 117 patients had at least 
1 clinical risk factor for SCD. The frequency of 
individual risk factors is shown in Figure 2. The 
percentage of patients with clinical risk factors in 
the LGE and no LGE groups is shown in Table 1. 
Only the difference in non sustained ventricular 
tachycardia (NSVT) between groups was statisti-
cally significant (p = 0.035).
Discussion
The risk stratification of patients with HCM 
is complex. Current guidelines recommend that 
an implantable cardiac defibrillator be considered 
in patients with 1 or more clinical risk factors for 
SCD [7]. However there is mounting evidence that 
LGE may be a much more specific predictor of poor 
prognosis in this condition, with adverse events 
being uncommon in patients without LGE [4]. 
The findings of this study are similar to previous 
reports, with regard to the proportion of patients 
with evidence of LGE [3]. In our group LGE was 
present in 68% of patients with HCM. However, 
when a risk factor is present in such a large propor-
tion of patients, further discriminators are required 
to improve predictive power. These may include 
factors such as LV mass and quantification of LGE 
as a percentage of myocardial mass, with higher 
percentage correlating with greater risk [4]. 
Traditional risk factors for SCD were present 
in 50 (43%) patients. Although NSVT was statisti-
cally more common in patients with LGE, overall 
the presence of any risk factor was not, suggesting 
that LGE is not simply a marker of commonly as-
sessed clinical risk factors. A significant proportion 
of patients (63%) without traditional clinical risk 
factors for SCD were found to have LGE on CMR 
and these patients would not currently be consi-
dered for therapy with an implantable cardiac defi-
brillator. The use of clinical risk factors in everyday 
practice presents several problems. Maximal wall 
thickness > 3 cm is present in a very small number 
of patients (only 1 in this study). Blood pressure 
response to exercise may be difficult to assess in 
many patients with mobility problems and can be 
unreliable in patients over 50 years of age [8]. Even 
family history of SCD may be difficult to quantify in 
patients who are unaware of their extended family 
tree. This study found that a significant proportion 
of patients with HCM who do not have clinical risk 
factors have evidence of LGE on CMR and may 
still be at increased risk of SCD. CMR with LGE 
provides a method of assessing myocardial repla-
cement fibrosis and with futher modification may 
be the most sensitive means of identifying patients 
at risk for cardiovascular events. 
Figure 2. Frequency of individual clinical risk factors in 
the study group.
Table 1. Occurrence of clinical risk factors for SCD according to presence or absence of LGE.
Late gadolinium  
enhancement
No late gadolinium  
enhancement
P 
0 risk factors 42 (63%) 25 (37%) 0.160
≥ 1 risk factor 38 (48%) 12 (32%) 0.160
Family history of SCD 17 (21%) 5 (14%) 0.447
NSVT on Holter 23 (29%) 4 (11%) 0.035
Abnormal stress test 7 (9%) 3 (8%) 1.000
Maximal wall thickness ≥ 3 cm 1 (1%) 0 (0%) 1.000 
LGE — late gadolinium enhancement; SCD — sudden cardiac death; NSVT — non sustained ventricular tachycardia
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Limitations of the study
This study has several limitations which must 
be considered. This is a retrospective analysis 
however for the purposes of assessing the rela-
tionship between LGE and clinical risk factors, 
a restrospective design was thought to be a reason- 
able approch. No endpoint data was therefore acqui-
red (with regard to cardiovascular events in the 
population). The extent of LGE was assessed qua-
litatively as currently our CMR software does not 
allow quantitative assessment, however qualitative 
analysis may allow more accurate assessment of 
risk. The small numbers of patients in some groups 
made analysis difficult, and may have contributed 
to a lack of association with LGE and clinical risk 
factors over all however the number of subjects 
was reasonable for a single centre study of this 
type and the frequency of risk factors reflects that 
in a real world population. 
Conclusions
1.  Patients with HCM are at increased risk of 
SCD, but identifying patients who may benefit 
from implantable defibrillators is difficult. 
2.  LGE is associated with adverse cardiovascular 
outcomes in HCM, but is present in a large 
proportion of patients. 
3.  Many patients without clinical risk factors for 
SCD have LGE and would not currently be 
considered for an implantable cardiac device. 
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